ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT07090330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Study identification
- NCT ID
- NCT07090330
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- ORKA-001 Induction Dose Drug
- ORKA-001 Maintenance Dose Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 17, 2025
- Primary completion
- Mar 24, 2026
- Completion
- Apr 30, 2027
- Last update posted
- Jun 30, 2026
2025 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oruka Therapeutics Investigative Site | Fountain Valley | California | 92708 | — |
| Oruka Therapeutics Investigative Site | Los Angeles | California | 90045 | — |
| Oruka Therapeutics Investigative Site | San Diego | California | 92123 | — |
| Oruka Therapeutics Investigative Site | Santa Ana | California | 92701 | — |
| Oruka Therapeutics Investigative Site | Santa Monica | California | 90403 | — |
| Oruka Therapeutics Investigative Site | Cromwell | Connecticut | 06416 | — |
| Oruka Therapeutics Investigative Site | Miami | Florida | 33126 | — |
| Oruka Therapeutics Investigative Site | Rolling Meadows | Illinois | 60008 | — |
| Oruka Therapeutics Investigative Site | Bowling Green | Kentucky | 42104 | — |
| Oruka Therapeutics Investigative Site | Rockville | Maryland | 20850 | — |
| Oruka Therapeutics Investigative Site | Boston | Massachusetts | 02111 | — |
| Oruka Therapeutics Investigative Site | Detroit | Michigan | 48202 | — |
| Oruka Therapeutics Investigative Site | New York | New York | 10023 | — |
| Oruka Therapeutics Investigative Site | New York | New York | 10029 | — |
| Oruka Therapeutics Investigative Site | Portland | Oregon | 97201 | — |
| Oruka Therapeutics Investigative Site | Norfolk | Virginia | 23502 | — |
| Oruka Therapeutics Investigative Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
Recently updated Plaque Psoriasis trials
Other public records listing Plaque Psoriasis. Sorted by last update posted; newest first. Not a recommendation.
- NCT05739435: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis Active, not recruiting
- NCT06220604: A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) Active, not recruiting
- NCT06143878: A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Active, not recruiting
- NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis Active, not recruiting
- NCT07250802: A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Recruiting
- NCT07116967: Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07090330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2026 · Synced Jul 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07090330 live on ClinicalTrials.gov.